Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma

NCT02366195 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

112

Enrollment

INDUSTRY

Sponsor class

Conditions

Unresected Stage IIIb to IVM1c Melanoma

Interventions

DRUG: Talimogene Laherparepvec

Sponsor

Amgen